We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

627 hedge funds and large institutions have $9.7B invested in State Street SPDR S&P Biotech ETF in 2025 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 160 increasing their positions, 279 reducing their positions, and 105 closing their positions.

New
Increased
Maintained
Reduced
Closed

33.37% more ownership

Funds ownership: 139.93% → 173.3% (+33%)

28% more capital inflows, than outflows

Capital inflows: $1.39B | Capital outflows: $1.09B

0% more funds holding in top 10

Funds holding in top 10: 15 → 15 (0)

9% less funds holding

Funds holding: 687 → 627 (-60)

34% less call options, than puts

Call options by funds: $1.48B | Put options by funds: $2.24B

43% less repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 279

56% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 105

Holders
627
Holders Change
-60
Holders Change %
-8.73%
% of All Funds
8.22%
Holding in Top 10
15
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
46
Increased
160
Reduced
279
Closed
105
Calls
$1.48​B
Puts
$2.24​B
Net Calls
-⁠$764​M
Net Calls Change
+$320​M

XBI Hedge Fund Activity: Q2 2025 in Review

627 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2025, worth a combined $9.7B — up 5.8% from $9.2B a quarter earlier.

Sellers outnumbered buyers: 105 funds closed out of XBI and 46 opened new positions — a net loss of 59 holders — while 279 trimmed existing stakes and 160 added.

The largest buyer was Goldman Sachs, adding an estimated $399M. The largest seller was UBS Group, cutting an estimated $246M.

  • 627 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2025, down from 687 in Q1 2025.
  • Funds reported $9.7B of State Street SPDR S&P Biotech ETF stock for Q2 2025, up 5.8% quarter-over-quarter.
  • 46 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2025 and 105 closed out, a net change of -59 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q2 2025 was Goldman Sachs, an estimated $399M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q2 2025 was UBS Group, an estimated $246M sold.

Based on aggregated 13F filings for Q2 2025.